$cat ./funds/brandon-capital.md
Brandon Capital
Melbourne · est. 2007 · A$1.4B AUM
Brandon Capital is the largest specialist life sciences investor in Australia and New Zealand, manager of Brandon BioCatalyst (formerly the Medical Research Commercialisation Fund, MRCF, renamed in March 2022). AUM exceeds A$1.4B following the July 2025 close of BB6.
Website
Stages
Seed, Series A, Series B, Series C
Fund size
A$1.4B
Partners
Stephen Thompson, Chris Nave, David Fisher
Founded
2007
HQ
Melbourne
$ls ./funds/brandon-capital/portfolio
Notable investments
- — Vaxxas
- — Fibrotech
- — Hatchtech
- — Spinifex Pharmaceuticals
- — Cynata Therapeutics
$git log --reverse --pretty=short ./funds/brandon-capital.md
Timeline
- 2007Brandon Capital founded in Melbourne.
- Mar 2023Closes BioMedical Translation Bridge fund at A$100M with federal co-funding.
- Oct 2024Vaxxas advances Phase II trials of needle-free vaccine patch with US partners.